Literature DB >> 18641033

Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology.

Jesús Rodríguez-Baño1, Lorena López-Cerero, María D Navarro, Paula Díaz de Alba, Alvaro Pascual.   

Abstract

OBJECTIVES: The aim of this study was to investigate the epidemiology of faecal carriage of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in the community. PATIENTS AND METHODS: Faecal carriage with ESBL-producing E. coli was studied in 53 outpatients with urinary tract infection (UTI) due to these organisms, 73 household members, 32 non-household relatives and 54 unrelated patients. Clonal relatedness of the isolates was investigated using repetitive extragenic palindromic-PCR and PFGE, and ESBLs were characterized by PCR and sequencing. Multivariate analysis was performed to investigate risk factors for faecal carriage.
RESULTS: The prevalence of faecal carriage was 67.9% in patients with UTI, 27.4% in household members, 15.6% in non-household relatives and 7.4% in unrelated patients. Being a relative of a patient with UTI was independently associated with an increased risk of being a carrier. Among the relatives, multivariate analysis showed that those eating their main meal outside their own home >15 days during the previous month were less likely to be faecal carriers (OR = 0.2; 95% CI: 0.06-0.6; P = 0.007). The faecal isolates of patients with UTI were CTX-M-producers in 66.6% and SHV-producers in 33.3% of the cases, while the percentages for other population groups were 40% to 55.5% and 50% to 75%, respectively. Of the 19 families with >1 carrier member, 8 families had 2 members who shared clonally related isolates, 8 families had 2 members carrying different clones producing the same enzymes and there were 3 families where all members had different enzyme-producing clones.
CONCLUSIONS: Our results suggest that both acquisition from a common source and person-to-person transmission might contribute to ESBL dissemination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18641033     DOI: 10.1093/jac/dkn293

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  59 in total

1.  High Heterogeneity of Multidrug-Resistant Enterobacteriaceae Fecal Levels in Hospitalized Patients Is Partially Driven by Intravenous β-Lactams.

Authors:  Eva M González-Barberá; Jaime Sanz; Ana Djukovic; Alejandro Artacho; Iván Peñaranda; Beatriz Herrera; María José Garzón; Miguel Salavert; José Luis López-Hontangas; Karina B Xavier; Bernhard Kuster; Laurent Debrauwer; Jean-Marc Rolain; Miguel A Sanz; Joao B Xavier; Carles Ubeda
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Occurrence of Clinically Important Lineages, Including the Sequence Type 131 C1-M27 Subclone, among Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Wastewater.

Authors:  Ryota Gomi; Tomonari Matsuda; Yasufumi Matsumura; Masaki Yamamoto; Michio Tanaka; Satoshi Ichiyama; Minoru Yoneda
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Matteo Bassetti; Francesco Giuseppe De Rosa; Teresa Spanu; Eugenia Di Meco; Angela Raffaella Losito; Andrea Parisini; Nicole Pagani; Roberto Cauda
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

4.  The Relative Impact of Community and Hospital Antibiotic Use on the Selection of Extended-spectrum Beta-lactamase-producing Escherichia coli.

Authors:  Derek R MacFadden; David N Fisman; William P Hanage; Marc Lipsitch
Journal:  Clin Infect Dis       Date:  2019-06-18       Impact factor: 9.079

5.  Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies.

Authors:  M Arnan; C Gudiol; L Calatayud; J Liñares; M Á Dominguez; M Batlle; J M Ribera; J Carratalà; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-10-30       Impact factor: 3.267

Review 6.  Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M.

Authors:  Paul-Louis Woerther; Charles Burdet; Elisabeth Chachaty; Antoine Andremont
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

7.  Transfer of plasmid-mediated CTX-M-9 from Salmonella enterica serotype Virchow to Enterobacteriaceae in human flora-associated rats treated with cefixime.

Authors:  S Faure; A Perrin-Guyomard; J M Delmas; P Chatre; M Laurentie
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

8.  Extended-spectrum-β-lactamase-producing Escherichia coli as intestinal colonizers in the German community.

Authors:  Giuseppe Valenza; Silke Nickel; Yvonne Pfeifer; Christoph Eller; Elzbieta Krupa; Verena Lehner-Reindl; Christiane Höller
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

9.  Acquisition of Extended-Spectrum β-Lactamases by Escherichia coli and Klebsiella pneumoniae in Gut Microbiota of Pilgrims during the Hajj Pilgrimage of 2013.

Authors:  Thongpan Leangapichart; Ndèye Méry Dia; Abiola Olumuyiwa Olaitan; Philippe Gautret; Philippe Brouqui; Jean-Marc Rolain
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

10.  Simultaneous gut colonisation and infection by ESBL-producing Escherichia coli in hospitalised patients.

Authors:  Johny Asir; Shashikala Nair; Sheela Devi; Kenchappa Prashanth; Rajagopalan Saranathan; Reba Kanungo
Journal:  Australas Med J       Date:  2015-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.